Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetirizine versus desloratadine in chronic spontaneous urticaria
IRCT20211219053449N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cetirizine and desloratadine in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Change in quality of life and Change in pruritus and urticaria control. Started Oct 2022; status: completed.
02
Drugs
cetirizinedesloratadine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on IRCT20211219053449N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211219053449N1.